# Terazosin And Metabolic Engagement in Alzheimer's Disease

Clinical trial · Qiang Zhang

- Archive id: nct:NCT07796308
- Published: 2026-09-01
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07796308
- Source URL: https://clinicaltrials.gov/study/NCT07796308
- Provenance: clinicaltrials

## Abstract

The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: TAME-AD
- status: NOT_YET_RECRUITING
- phase: PHASE2
- study type: INTERVENTIONAL
- enrollment: 100
- sponsor: Qiang Zhang
- conditions: Alzheimer s Disease
- interventions: DRUG: Terazosin (Hytrin); OTHER: Placebo
- start date: 2027-08-01
- start date type: ESTIMATED
- primary completion date: 2031-07-31
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Alzheimer's, Parkinson's & Neurodegeneration](https://space-kitty.com/topics/neurodegeneration)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.